Ischemic stroke is a cerebrovascular disease with high clinical incidence rate,making it one of the main causes of death and permanent disability worldwide. Currently,acute phase thrombolytic therapy and neuroprotective measures are often limited by narrow treatment time windows and bleeding complications,leading to many patients missing the optimal opportunity for thrombolytic therapy and resulting in poor prognosis and a lack of ideal treatment methods. Mesenchymal stem cell transplantation therapy is a new approach for treating ischemic stroke that has garnered significant attention due to its advantages,such as abundant sources,multi-directional differentiation potential,low immunogenicity,and paracrine effects. Animal experiments have confirmed that mesenchymal stem cell transplantation can alleviate neurological defects,promote nerve damage repair and regeneration,and is safe and feasible,offering hope for the treatment of ischemic stroke. However,determining the optimal timing and dosage of mesenchymal stem cell transplantation remains a major challenge for its clinical application. This article provides a review of preclinical studies on the biological activity of mesenchymal stem cells,as well as the administration routes,time windows,doses,efficacy,molecular mechanisms,and safety of mesenchymal stem cell transplantation for the treatment of ischemic stroke in animal models. In addition,the limitations of preclinical studies on mesenchymal stem cell transplantation therapy are discussed with the aim of providing a theoretical basis for the clinical translational research of mesenchymal stem cell transplantation.
mesenchymal stem cellischemic strokestem cell transplantationpreclinical studyregenerative medicine
万方数据
维普
